6 Analysts Have This to Say About Cara Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Cara Therapeutics (NASDAQ:CARA) received 5 bullish and 1 somewhat bearish ratings from analysts. The average 12-month price target for the company is $18.17, which has increased by 39.77% over the past month.
August 08, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cara Therapeutics received mostly bullish ratings from analysts, with an increasing 12-month price target, indicating positive sentiment.
The majority of analyst ratings for Cara Therapeutics are bullish, indicating a positive outlook for the company. Additionally, the average 12-month price target has increased significantly over the past month, suggesting that analysts expect the stock price to rise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100